PledPharma is a pharmaceutical drug development company with unique, integrated capabilities, focusing on improving the treatment of serious diseases with a major unmet medical need.
The Company currently has two projects in clinical phase:
PledOx® is a first-in-class drug candidate designed to prevent nerve damage caused by chemotherapy. A global Phase III program is ongoing.
Aladote® is a first-in-class drug candidate developed to reduce liver damage caused by paracetamol poisoning. A proof-of-principle study, Phases Ib/IIa, has been successfully completed and a pivotal pase II/III study is planned to be initiated mid-2020.
- protects the peripheral nerves
Protection against the nerve damage that often occurs in connection with chemotherapy.
- protects the liver
Prevents acute liver failure in paracetamol poisoning.